Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Castration-Resistant Prostate Cancer

  • Manfred Schwab
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_6802-2


Androgen deprivation therapy (ADT) has been a mainstay in prostate cancer therapy. After an excellent clinical response to ADT, however, prostate cancer returns as a therapy resistant and deadly form, resulting in a short survival time of 18–24 months. This form of prostate cancer, now known as castration-resistant prostate cancer (CRPC), often metastasizes to the bone and results in the clinical symptoms of pain. A great challenge is the discovery of new chemotherapy drugs that can increase overall survival of patients with recurrent CRPC.



Prostate Cancer Cancer Research Survival Time Clinical Symptom Clinical Response 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.German Cancer Research Center (DKFZ)HeidelbergGermany